Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma

NCT04923529 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT04923529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04923529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2021
Completion date
December 31, 2024
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas cancer